90P Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma

Anal squamous cell carcinoma (SCCA) is an uncommon malignancy with a rising incidence, that has a high cure rate in its early stages. However, there is an unmet need for a reliable, non-invasive method to monitor response to treatment and assist in surveillance. Standard-of-care surveillance primarily relies on radiological imaging and anoscopy with biopsy, which can potentially lead to false positive and negative results. Circulating tumor DNA (ctDNA) testing has shown great promise in other solid tumors for monitoring disease progression and detecting relapse in real time.